Samyang Biopharm was spun off from Samyang Holdings on November 1, 2025 and relisted on the KOSPI on November 24, 2025. Its business spans biodegradable sutures, aesthetic medical devices, oncology drugs and drug delivery technology.
In the two months from November 1 to December 31, 2025, the medical device segment generated revenue of KRW 17.9 billion and operating profit of KRW 6.1 billion, making it the largest profit contributor.
The pharmaceutical segment posted revenue of KRW 10.6 billion and operating profit of KRW 1.0 billion, while the other segment recorded a loss. Per company statements cited in the press, sutures account for 45% of revenue and the company holds the global number one share by thread supply volume.
Over the same two months, exports were KRW 16.8 billion and domestic sales were KRW 11.8 billion, an export share of about 59%. Another press report said more than 80% of revenue comes from overseas, so the basis of the figures differs.
The oncology portfolio covers seven solid tumor types and five blood cancers, and a dedicated cytotoxic injectable plant with annual capacity of 5 million vials holds both Japanese and European GMP certifications.
The aesthetic lineup includes the Croquie thread lift and the Lapulen filler, which launched in Indonesia in 2023 and was supported by a China partnership signed the same year.
In anticancer contract manufacturing it competes with large CDMO players such as Samsung Biologics, and it positions its dedicated facility and dual GMP certification as differentiators.